ERD: Erosive reflux disease; GERD: Gastroesophageal reflux disease; NERD: Non-erosive reflux disease; PPI: Proton pump inhibitor, Vonoprazan
A cross-sectional study evaluated the clinical characteristics of rGERD and their prevalence in Indian patients with symptoms suggestive of GERD and no response to PPIs for 8 weeks.1
Heartburn and regurgitation were prevalent in 92% and 96% of patients, respectively, making them the most dominant symptoms in the population.1
Atypical symptoms were detected in 39% of cases, and 72% of patients reported both typical and atypical symptoms.1
Endoscopic findings showed 33% of patients with NERD and 67% with ERD.1
Hiatal hernia was prevalent in 48% of patients while being more prominent in ERD cases (53.7%) than NERD cases (18%).1
Histopathological alterations suggested distal esophagus inflammation in 56% of cases, with basal cell hyperplasia in 54% and elongation of papillae in 21%.
ERD: Erosive reflux disease; GERD: Gastroesophageal reflux disease; NERD: Non-erosive reflux disease; PPI: Proton pump inhibitor.
Vono 20-Always on Duty
Vono, containing Vonoprazan molecule, is a Potassium Competitive Acid Blocker which helps in treatment of Refractory GERD, Erosive Esophagitis, H.Pylori, Gastric & Duodenal Ulcers
